The University of Chicago Header Logo

Connection

Michael H. Davidson to Dyslipidemias

Back to Details
This is a "connection" page, showing publications Michael H. Davidson has written about Dyslipidemias.
Michael H. Davidson
Connection Strength
14.786
Dyslipidemias
  1. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat Med. 2022 08; 28(8):1672-1678.
    View in: PubMed
    Score: 0.787
  2. How I treat statin-associated side effects in an outpatient setting. Future Cardiol. 2021 10; 17(7):1249-1260.
    View in: PubMed
    Score: 0.706
  3. Recent advances and emerging therapies in management of dyslipidemias. Trends Cardiovasc Med. 2021 10; 31(7):419-424.
    View in: PubMed
    Score: 0.687
  4. How Genomics Is Personalizing the Management of Dyslipidemia and Cardiovascular Disease Prevention. Curr Cardiol Rep. 2018 10 17; 20(12):138.
    View in: PubMed
    Score: 0.604
  5. The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients. J Cardiovasc Pharmacol Ther. 2019 01; 24(1):54-61.
    View in: PubMed
    Score: 0.591
  6. Evolution of Omega-3 Fatty Acid Therapy and Current and Future Role in the Management of Dyslipidemia. Cardiol Clin. 2018 May; 36(2):277-285.
    View in: PubMed
    Score: 0.577
  7. Can We Cure Atherosclerosis? Rev Cardiovasc Med. 2018; 19(S1):S20-S24.
    View in: PubMed
    Score: 0.571
  8. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety. Rev Cardiovasc Med. 2018; 19(S1):S31-S46.
    View in: PubMed
    Score: 0.571
  9. Changing characteristics of statin-related cIMT trials from 1988 to 2006. Atherosclerosis. 2016 Mar; 246:121-9.
    View in: PubMed
    Score: 0.494
  10. Beta-2 Agonism: A Potential Therapeutic Target for Dyslipidemia. EBioMedicine. 2015 Apr; 2(4):284.
    View in: PubMed
    Score: 0.470
  11. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). Arterioscler Thromb Vasc Biol. 2014 Jun; 34(6):1298-306.
    View in: PubMed
    Score: 0.442
  12. Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose. J Clin Lipidol. 2013 Sep-Oct; 7(5):423-32.
    View in: PubMed
    Score: 0.417
  13. Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovasc Drugs Ther. 2012 Aug; 26(4):349-58.
    View in: PubMed
    Score: 0.393
  14. Pharmacotherapy: Implications of high-dose statin link with incident diabetes. Nat Rev Cardiol. 2011 Aug 02; 8(10):543-4.
    View in: PubMed
    Score: 0.366
  15. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Clin Ther. 2009 Dec; 31(12):2824-38.
    View in: PubMed
    Score: 0.326
  16. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. Am J Cardiol. 2008 Dec 22; 102(12A):19L-27L.
    View in: PubMed
    Score: 0.306
  17. Niacin therapy: an evolving paradigm for the management of mixed dyslipidemia and low high-density lipoprotein cholesterol. Introduction. Am J Cardiol. 2008 Apr 17; 101(8A):1B-2B.
    View in: PubMed
    Score: 0.292
  18. Niacin use and cutaneous flushing: mechanisms and strategies for prevention. Am J Cardiol. 2008 Apr 17; 101(8A):14B-19B.
    View in: PubMed
    Score: 0.292
  19. Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy. Am J Cardiol. 2008 Apr 17; 101(8A):27B-35B.
    View in: PubMed
    Score: 0.292
  20. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs. 2008; 8(2):69-81.
    View in: PubMed
    Score: 0.286
  21. The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review. Expert Opin Pharmacother. 2007 Oct; 8(15):2569-78.
    View in: PubMed
    Score: 0.281
  22. Squalene synthase inhibition: a novel target for the management of dyslipidemia. Curr Atheroscler Rep. 2007 Jan; 9(1):78-80.
    View in: PubMed
    Score: 0.267
  23. Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease. Am Heart Hosp J. 2007; 5(4):210-6.
    View in: PubMed
    Score: 0.267
  24. Safety considerations with fibrate therapy. Am J Cardiol. 2007 Mar 19; 99(6A):3C-18C.
    View in: PubMed
    Score: 0.265
  25. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol. 2006 Aug 21; 98(4A):27i-33i.
    View in: PubMed
    Score: 0.256
  26. Ethnic differences in achievement of cholesterol treatment goals. Results from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology II. J Gen Intern Med. 2006 Apr; 21(4):320-6.
    View in: PubMed
    Score: 0.253
  27. Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II). J Cardiometab Syndr. 2006; 1(5):295-300.
    View in: PubMed
    Score: 0.249
  28. Pharmacokinetic interactions between statins and fibrates. Am J Cardiol. 2005 Nov 07; 96(9A):44K-49K; discussion 34K-35K.
    View in: PubMed
    Score: 0.245
  29. Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am J Cardiol. 2005 Nov 07; 96(9A):3K-13K; discussion 34K-35K.
    View in: PubMed
    Score: 0.244
  30. Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin Pharmacother. 2005 Jan; 6(1):131-9.
    View in: PubMed
    Score: 0.232
  31. Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation. Prev Cardiol. 2005; 8(4):244-9.
    View in: PubMed
    Score: 0.232
  32. Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition. Eur Heart J Cardiovasc Pharmacother. 2023 02 02; 9(2):148-155.
    View in: PubMed
    Score: 0.203
  33. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. Endocr Pract. 2020 Oct; 26(10):1196-1224.
    View in: PubMed
    Score: 0.173
  34. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Atherosclerosis. 2019 09; 288:85-93.
    View in: PubMed
    Score: 0.159
  35. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. Atherosclerosis. 2019 09; 288:194-202.
    View in: PubMed
    Score: 0.158
  36. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Endocr Pract. 2017 Apr; 23(Suppl 2):1-87.
    View in: PubMed
    Score: 0.136
  37. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE - EXECUTIVE SUMMARYComplete Appendix to Guidelines available at http://journals.aace.com. Endocr Pract. 2017 Apr 02; 23(4):479-497.
    View in: PubMed
    Score: 0.134
  38. The future of n-3 polyunsaturated fatty acid therapy. Curr Opin Lipidol. 2016 12; 27(6):570-578.
    View in: PubMed
    Score: 0.133
  39. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial. Clin Ther. 2014 Aug 01; 36(8):1211-22.
    View in: PubMed
    Score: 0.112
  40. [Official document of the International Society of Atherosclerosis: general recommendations for treatment of dyslipidemia. Executive summary]. Clin Investig Arterioscler. 2014 Jan-Feb; 26(1):33-7.
    View in: PubMed
    Score: 0.107
  41. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response. Am J Cardiovasc Drugs. 2012 Apr 01; 12(2):117-25.
    View in: PubMed
    Score: 0.096
  42. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies. J Clin Lipidol. 2012 Nov-Dec; 6(6):534-44.
    View in: PubMed
    Score: 0.095
  43. Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk. Diabetes Obes Metab. 2012 Jan; 14(1):30-9.
    View in: PubMed
    Score: 0.094
  44. Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (= 2 mg/L). cmb@bcm.tmc.edu. J Clin Lipidol. 2011 Sep-Oct; 5(5):401-7.
    View in: PubMed
    Score: 0.091
  45. Drugs in development for management of lipoprotein disorders. J Clin Lipidol. 2011 Mar-Apr; 5(2):66-75.
    View in: PubMed
    Score: 0.088
  46. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Am J Cardiovasc Drugs. 2010; 10(2):73-84.
    View in: PubMed
    Score: 0.082
  47. A clinical puzzle: fibrates and homocysteine elevation: editorial to: "fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine" by M. Lever et al. Cardiovasc Drugs Ther. 2009 Oct; 23(5):341-2.
    View in: PubMed
    Score: 0.081
  48. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol. 2009 Jul 01; 104(1):74-81.
    View in: PubMed
    Score: 0.079
  49. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Cardiol Clin. 2008 Nov; 26(4):547-60.
    View in: PubMed
    Score: 0.076
  50. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis. 2009 May; 204(1):208-15.
    View in: PubMed
    Score: 0.075
  51. Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet. Clin Drug Investig. 2008; 28(10):615-23.
    View in: PubMed
    Score: 0.071
  52. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme. Clin Drug Investig. 2008; 28(10):625-34.
    View in: PubMed
    Score: 0.071
  53. Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey. Am Heart J. 2006 Nov; 152(5):976-81.
    View in: PubMed
    Score: 0.066
  54. Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects. Clin Cardiol. 2006 Jun; 29(6):268-73.
    View in: PubMed
    Score: 0.064
  55. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opin Drug Saf. 2015 Jun; 14(6):935-55.
    View in: PubMed
    Score: 0.030
  56. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis. 2009 May; 53(5):741-50.
    View in: PubMed
    Score: 0.019
  57. Flushing ASsessment Tool (FAST): psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy. Clin Drug Investig. 2009; 29(4):215-29.
    View in: PubMed
    Score: 0.019
  58. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol. 2008 Mar 01; 101(5):625-30.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.